journal
MENU ▼
Read by QxMD icon Read
search

Hematology/oncology Clinics of North America

journal
https://read.qxmd.com/read/30497681/cutaneous-malignancy
#1
EDITORIAL
Nicole R LeBoeuf, Cecilia Larocca
No abstract text is available yet for this article.
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497680/erratum
#2
(no author information available yet)
No abstract text is available yet for this article.
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497679/cutaneous-sarcomas
#3
REVIEW
Mehul D Bhatt, Vinod E Nambudiri
Cutaneous sarcomas are rare malignancies that may present with a variety of clinical manifestations. This article focuses on 4 of the most common cutaneous sarcomas (Kaposi sarcoma, cutaneous angiosarcoma, dermatofibrosarcoma protuberans, and cutaneous leiomyosarcoma) and reviews clinical, diagnostic, and therapeutic aspects of these rare skin malignancies.
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497678/extramammary-paget-s-disease
#4
REVIEW
Mackenzie Asel, Nicole R LeBoeuf
Extramammary Paget disease (EMPD) is a rare cutaneous malignancy most commonly affecting the genitals, perineum, and perianal area of the elderly. Despite its rarity, to those impacted, the disease and its treatment can have a tremendous impact on quality of life. Commonly confined to the epidermis, EMPD can be invasive, associated with contiguous extension or upward pagetoid spread of underlying malignancy or with distant synchronous malignancy. Because of its association with other cancers, formal evaluation is warranted...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497677/malignant-sweat-gland-tumors
#5
REVIEW
Christine S Ahn, Omar P Sangüeza
Malignant sweat gland neoplasms are a confusing area within dermatopathology, with many entities reported under several designations in the literature. This review describes the key clinical and histopathologic features of select malignant adnexal neoplasms, including porocarcinoma, papillary carcinoma, adenoid cystic carcinoma, cribriform carcinoma, apocrine hidradenocarcinoma, malignant mixed tumor of the skin, syringoid carcinoma, cylindrocarcinoma, spiradenocarcinoma, mucinous carcinoma, polymorphous sweat gland carcinoma, microcystic adnexal carcinoma, secretory carcinoma of the skin, and primary cutaneous signet ring cell carcinoma...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497676/merkel-cell-carcinoma-review
#6
REVIEW
Yun Xue, Manisha Thakuria
Merkel cell carcinoma is a rare and aggressive cutaneous malignancy of neuroendocrine origin-an often-missed diagnosis due to the wide histopathologic differential diagnosis of malignant small blue cell tumors. The advent of electron microscopy and immunohistochemistry staining for cytokeratin 20, a shared neuroendocrine marker, greatly improved diagnostic accuracy. Over the past decade, staging, treatment, and surveillance of the cancer have progressed at a remarkably rapid pace. Herein, the authors provide an update on the current guidelines around diagnosis and management and review the exciting advancements on the horizon...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497675/cutaneous-melanoma-a-review-in-detection-staging-and-management
#7
REVIEW
Rebecca I Hartman, Jennifer Y Lin
Melanoma is an increasingly common cancer in the United States, although mortality has likely stabilized. Diagnosis relies on a skilled practitioner with the aid of dermoscopy and initial local surgical management is a mainstay of treatment. Recent changes in staging emphasize continued use of sentinel lymph node biopsy to aid in prognostication although routine complete lymph node dissection has fallen out of favor. Advances in systemic treatment options, including targeted and immunotherapy, have dramatically changed the treatment paradigm for advanced melanoma and improved outcome...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497674/cutaneous-metastasis
#8
REVIEW
John D Strickley, Alfred Bennett Jenson, Jae Yeon Jung
Although rare, cutaneous metastases portend a poor prognosis and are often an indicator of widespread disease. Breast cancer and melanoma are the most common types of cancer that are associated with spread to and within the skin; however, other malignancies, such as lung, colon, head and neck, and hematologic, have been described with a degree of relative frequency. A variety of clinical appearances and syndromes of cutaneous metastases are presented and described in this article. Possible treatment options, including skin-directed therapies and immunotherapies, are also discussed...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497673/cutaneous-involvement-of-hematologic-malignancies
#9
REVIEW
Nancy Kaddis, David Fisher, Eric D Jacobsen
In reviewing cutaneous manifestations of various hematologic malignancies, the authors focus on secondary cutaneous lymphomas and cutaneous manifestations of histiocyte disorders. Secondary cutaneous lymphomas are defined as skin lesions that develop secondary to infiltration by systemic lymphomas with predominantly extracutaneous involvement. In their review of histiocytic disorders with skin involvement, the authors focus on Langerhans cell histiocytosis and Rosai-Dorfman disease. Their review emphasizes the histology, pathophysiology, clinical presentation, prognosis, and treatments available for these diseases...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497672/cutaneous-b-cell-lymphoma
#10
REVIEW
Amrita Goyal, Robert E LeBlanc, Joi B Carter
Primary cutaneous B-cell lymphomas are non-Hodgkin lymphomas that present in the skin without evidence of extracutaneous involvement at diagnosis. There are 3 types of primary cutaneous B-cell lymphomas: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg-type. Because it is most frequently diagnosed on skin biopsy, intravascular large B-cell lymphoma is commonly included with pcBCL. A complicating factor in diagnosing primary cutaneous B-cell lymphomas is that they can appear histologically identical to their extracutaneous counterparts...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497671/rare-cutaneous-t-cell-lymphomas
#11
REVIEW
Fabiana Damasco, Oleg E Akilov
Rare lymphoma includes the entities that occur in less than 1% of cases of all lymphomas. Although the percentage is low, there are more than eight lymphomas classified as rare lymphomas. This article describes clinical presentation, diagnosis, prognosis, and management of the most common rare lymphomas, including primary cutaneous γδ T-cell lymphoma, primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder, primary cutaneous acral CD8+ T-cell lymphoma, primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, extranodal NK-/T-cell lymphoma, nasal type, and subcutaneous panniculitis-like T-cell lymphoma...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497670/basal-cell-carcinoma-review
#12
REVIEW
Dennis P Kim, Kylee J B Kus, Emily Ruiz
Basal cell carcinoma (BCC) is the most common malignancy and the incidence is rising. BCCs have low mortality but can cause significant morbidity primarily through local destruction. The pathogenesis is linked to the interplay between environmental and patient-derived characteristics. There are multiple therapeutic modalities, and appropriate selection requires knowledge of complications, cosmetic outcomes, and recurrence rates. This article reviews the epidemiology, staging, treatment, and prevention of BCC...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497669/a-review-of-primary-cutaneous-cd30-lymphoproliferative-disorders
#13
REVIEW
Cynthia Chen, Yuhan D Gu, Larisa J Geskin
Primary cutaneous CD30+ lymphoproliferative diseases (LPDs) comprise a range of diseases (LyP, pcALCL, and borderline lesions) with broad histologic and phenotypical characteristics, although they all share the common feature of a favorable prognosis notwithstanding histology suggestive of a high-grade lymphoma. Given their cytomorphologic similarities, accurate diagnosis and workup are needed to differentiate these distinct entities in order to best use novel biologic therapies and avoid aggressive overtreatment...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497668/mycosis-fungoides-and-s%C3%A3-zary-syndrome-an-update
#14
REVIEW
Cecilia Larocca, Thomas Kupper
Cutaneous T-cell lymphomas are a heterogeneous collection of non-Hodgkin lymphomas that arise from skin-tropic memory T lymphocytes. Among them, mycosis fungoides (MF) and Sézary syndrome (SS) are the most common malignancies. Diagnosis requires the combination of clinical, pathologic, and molecular features. Significant advances have been made in understanding the genetic and epigenetic aberrations in SS and to some extent in MF. Several prognostic factors have been identified. The goal of treatment is to minimize morbidity and limit disease progression...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30497667/cutaneous-squamous-cell-carcinoma
#15
REVIEW
Abigail Waldman, Chrysalyne Schmults
Cutaneous squamous cell carcinoma represents 20% of all skin cancers, resulting in 1 million cases in the United States each year. The lifetime risk of developing squamous cell carcinoma continues to increase annually and will likely continue to increase because of the aging population. Most cutaneous squamous cell carcinoma are treated locally, with a subset leading to recurrence, metastasis, and death. This review of cutaneous squamous cell carcinoma covers incidence, recurrence rates, mortality rates, risk factors, staging systems, treatment, prevention, and monitoring...
February 2019: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30390771/ovarian-cancer
#16
EDITORIAL
Ursula A Matulonis
No abstract text is available yet for this article.
December 2018: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30390770/targeting-dna-damage-response-and-repair-as-a-therapeutic-strategy-for-ovarian-cancer
#17
REVIEW
Panagiotis A Konstantinopoulos, Ursula A Matulonis
Large-scale genomic studies have demonstrated that ovarian cancer is characterized by frequent genetic and epigenetic alterations of gene members of the homologous recombination repair pathway. Homologous recombination repair deficiency induces genomic instability and hyperdependence on alternative DNA repair mechanisms, and is associated with enhanced sensitivity to double-strand break-inducing agents such as platinum analogues and poly(adenosine diphosphate)-ribose polymerase inhibitors. The authors review the DNA repair pathway alterations that are present in ovarian cancer, and discuss current and emerging therapeutic approaches that target the DNA damage response and repair focusing on chemotherapy and poly(adenosine diphosphate)-ribose polymerase inhibitors...
December 2018: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30390769/mechanisms-of-drug-resistance-in-high-grade-serous-ovarian-cancer
#18
REVIEW
Alison E Freimund, Jessica A Beach, Elizabeth L Christie, David D L Bowtell
Resistance in ovarian cancer is driven by a range of mechanisms, some of which are therapy specific whereas others confer multidrug resistance. This review outlines our current understanding of the heterogeneous mechanisms of both primary and acquired drug resistance in high-grade serous ovarian cancer with a focus on the most common therapeutics, including platinum and taxanes. Current therapeutic strategies for overcoming resistance, including the use of non-P- glycoprotein substrate therapies, are outlined, with an emphasis on the importance of developing resistance biomarkers to guide future therapy approaches and improve patient outcomes...
December 2018: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30390768/management-and-treatment-of-recurrent-epithelial-ovarian-cancer
#19
REVIEW
Shannon Armbruster, Robert L Coleman, Jose Alejandro Rauh-Hain
Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival...
December 2018: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/30390767/diagnosis-and-treatment-of-ovarian-cancer
#20
REVIEW
Brian Orr, Robert P Edwards
Epithelial ovarian cancer classically presents with vague persistent gastrointestinal, urologic, or nonacute abdominal/pelvic symptoms (bloating, early satiety, discomfort). Ultimately, a pelvic examination or imaging identifies an adnexal mass typically with accompanied advanced peritoneal dissemination. Management involves aggressive cytoreductive surgery in combination with platinum and taxane chemotherapy. Over the last 20 years, optimal resection and mode and timing of chemotherapy have evolved. The authors review the initial diagnosis and management and present the available data and recommendations to guide the decision tree of when to use neoadjuvant, intraperitoneal, HIPEC, dose-dense, and maintenance chemotherapy in the front-line treatment of epithelial ovarian cancer...
December 2018: Hematology/oncology Clinics of North America
journal
journal
29616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"